Compare FTAI Aviation Ltd (FTAI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? FTAI Aviation Ltd trades at $159.09 (market cap $16.75B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: FTAI Aviation Ltd is far larger — about 17.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and FTAI Aviation Ltd pays a 1.23% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FTAI | MRVI | |
|---|---|---|
Market Cap | $16.75B | $977.37M |
Volume | 2,940,634 | 2,742,564 |
Sector | Industrials | Health |
52-Week High | $310.04 | $9.00 |
52-Week Low | $152.80 | $2.83 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $19.87B | $1.08B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, up 0.81% today, but technical indicators signal a bearish trend with key support at $163 and resistance at $169. The company reported strong 2025 revenue of $2.51 billion and net income of $501 million, though recent quarters have missed EPS expectations. Recent developments include a $500 million share buyback program and a strategic acquisition of 27 Boeing 737-700 aircraft, highlighting growth initiatives in aerospace services.
The outlook is mixed: analyst consensus is unanimously bullish with a $321.25 price target, but risks include volatile cash flows and competitive pressures. Upside potential hinges on execution of the buyback and aerospace segment growth, while earnings misses and negative operating cash flow pose near-term challenges for investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
